FIELD: pharmacology.
SUBSTANCE: invention is intended for treatment of cancer in a patient having AKT1 mutation at position L52 or D323. The presence of L52 or D323 mutation in the patient's AKT1 gene is determined. A patient with such mutation receives (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one or a pharmaceutically acceptable salt thereof.
EFFECT: invention provides effective cancer treatment.
17 cl, 18 dwg, 3 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PRODUCTION OF HYDROXYLATED CYCLOPENTAPYRIMIDINE COMPOUNDS AND THEIR SALTS | 2013 |
|
RU2642311C2 |
| HYDROXYLATED AND METHOXYLATED CYCLOPENTA[B]PYRIMIDINES AS PROTEIN KINASE INHIBITORS | 2007 |
|
RU2478632C2 |
| FORMS AND COMPOSITION OF PYRIMIDINYL CYCLOPENTANE COMPOUNDS, COMPOSITIONS AND METHODS THEREOF | 2013 |
|
RU2650511C2 |
| COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ABIRATERONE, AND APPLICATION METHODS | 2012 |
|
RU2631240C2 |
| HYDROXYLATED PYRIMIDYLCYCLOPENTANES AS PROTEIN KINASE (AKT) INHIBITORS | 2009 |
|
RU2504542C2 |
| HYDROXYLATED PYRIMIDYL CYCLOPENTANE AS PROTEINKINASE (ACT) INHIBITOR | 2009 |
|
RU2520735C2 |
| CYCLOPENTA(D)PYRIMIDINES AS PROTEIN KINASE AKT INHIBITORS | 2007 |
|
RU2481336C2 |
| PYRIMIDYL CYCLOPENTANES AS AKT-PROTEIN KINASE INHIBITORS | 2008 |
|
RU2486178C2 |
| METHOD OF PRODUCING PYRIMIDINYLCYCLOPENTANE COMPOUNDS | 2014 |
|
RU2702355C1 |
| METHOD FOR PRODUCTION OF HYDROXYLATED CYCLOPENTYL PYRIMIDINE COMPOUNDS | 2013 |
|
RU2643811C2 |
